These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35288342)

  • 21. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
    Anstee QM; Lawitz EJ; Alkhouri N; Wong VW; Romero-Gomez M; Okanoue T; Trauner M; Kersey K; Li G; Han L; Jia C; Wang L; Chen G; Subramanian GM; Myers RP; Djedjos CS; Kohli A; Bzowej N; Younes Z; Sarin S; Shiffman ML; Harrison SA; Afdhal NH; Goodman Z; Younossi ZM
    Hepatology; 2019 Nov; 70(5):1521-1530. PubMed ID: 31271665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Cassinotto C; Boursier J; Paisant A; Guiu B; Irles-Depe M; Canivet C; Aube C; de Ledinghen V
    Hepatology; 2021 Jun; 73(6):2196-2205. PubMed ID: 33236409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
    Vieira Barbosa J; Lai M
    Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patients.
    Ito T; Nguyen VH; Tanaka T; Park H; Yeh ML; Kawanaka M; Arai T; Atsukawa M; Yoon EL; Tsai PC; Toyoda H; Huang JF; Henry L; Jun DW; Yu ML; Ishigami M; Nguyen MH; Cheung RC
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1013-1022.e6. PubMed ID: 35654298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD.
    Bilson J; Scorletti E; Bindels LB; Afolabi PR; Targher G; Calder PC; Sethi JK; Byrne CD
    Nutr Diabetes; 2021 Oct; 11(1):32. PubMed ID: 34663793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease.
    Lee DH; Sung SU; Lee YK; Lim IH; Jang H; Joo SK; Park JH; Chang MS; So YH; Kim W;
    Aliment Pharmacol Ther; 2022 Apr; 55(8):994-1007. PubMed ID: 35005800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Diagnostic Test Meta-Analysis Evaluating Imaging-Based and Blood Biomarker-Based Assessment Tools for Fibrosis After Liver Transplantation.
    Ng CH; Tan DJH; Lim XC; Yong JN; Syn N; Soon GST; Huang DQ; Xiao J; Lim GEH; Lim WH; Tan EXX; Dan YY; Noureddin M; Siddiqui MS; Muthiah MD
    Liver Transpl; 2022 Apr; 28(4):659-669. PubMed ID: 34714966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.
    Kosick HM; Keyrouz A; Adeyi O; Sebastiani G; Patel K
    Dig Dis Sci; 2021 Nov; 66(11):4046-4057. PubMed ID: 33389416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease.
    Takeuchi H; Sugimoto K; Oshiro H; Iwatsuka K; Kono S; Yoshimasu Y; Kasai Y; Furuichi Y; Sakamaki K; Itoi T
    J Med Ultrason (2001); 2018 Apr; 45(2):243-249. PubMed ID: 29128938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
    Thiele M; Madsen BS; Hansen JF; Detlefsen S; Antonsen S; Krag A
    Gastroenterology; 2018 Apr; 154(5):1369-1379. PubMed ID: 29317276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
    Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
    Boursier J; Vergniol J; Sawadogo A; Dakka T; Michalak S; Gallois Y; Le Tallec V; Oberti F; Fouchard-Hubert I; Dib N; Rousselet MC; Konaté A; Amrani N; de Ledinghen V; Calès P
    Liver Int; 2009 Nov; 29(10):1507-15. PubMed ID: 19725892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Imajo K; Honda Y; Kobayashi T; Nagai K; Ozaki A; Iwaki M; Kessoku T; Ogawa Y; Takahashi H; Saigusa Y; Yoneda M; Kirikoshi H; Utsunomiya D; Aishima S; Saito S; Nakajima A
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):908-917.e11. PubMed ID: 33340780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.